EGFR mutation-positive NSCLC
Oncology · 2019–2019
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| osimertinib First-line treatment of locally advanced or metastatic (Stage IIIB or IV) EGFR mutation-positive non-small cell lung cancer (NSCLC) in treatment-naïve patients. | Jul 2019 | Not recommended | 10 individuals Lung Foundation Australia · Medical Oncology Group |
Who spoke
Lung Foundation Australia · Medical Oncology Group
What the PBS pays
$201M in government benefit over 2024–25, across 26,282 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| osimertinib | $200.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.